Mifepristone

Structure of Mifepristone (CAS NO.84371-65-3):

Index of Refraction: 1.623
Molar Refractivity: 127.71 cm³
Molar Volume: 362 cm³
Polarizability: 50.62×10^-24cm³
Surface Tension: 54 dyne/cm
Density: 1.18 g/cm³
Flash Point: 334 °C
Enthalpy of Vaporization: 97.77 kJ/mol 
Melting Point: 195-198°C
Boiling Point: 628.6 °C at 760 mmHg
Vapour Pressure: 1.14E-16 mmHg at 25°C 
Physical Appearance: Pale Yellow Solid
Product Categories: Steroids;Hormone;Acetylenes;Biochemistry;Functionalized Acetylenes;Hydroxyketosteroids;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Intracellular receptor;Nuclear Receptors 
Canonical SMILES: CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O
Isomeric SMILES: CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
InChI: InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
InChIKey: VKHAHZOOUSRJNA-GCNJZUOMSA-N

In 1980, Mifepristone (CAS NO.84371-65-3) was discovered by researchers at Roussel Uclaf of France while they were studying glucocorticoid receptor antagonists.étienne-émile Baulieu recognized its anti-progesterone activities and saw its potential for the induction of a medical abortion. Clinical testing began in 1982. The drug was first licensed in France in 1988, for use in combination with a prostaglandin, under the name Mifegyne. After license approval but before market release, Roussel Uclaf announced it would abandon distribution of the drug, bowing to pressure from pro-life groups and the threat of a boycott. However, two days later, the French government, part owner of Roussel Uclaf, intervened, leading to the resumption of production and distribution of RU-486.

 Mifepristone (CAS NO.84371-65-3) is a synthetic steroid compound used as a pharmaceutical. It is used as an abortifacient in the first two months of pregnancy, and in smaller doses as an emergency contraceptive.
Other medical applications of mifepristone(84371-65-3)  that have been studied in Phase II clinical trials include regular long-term use as an oral contraceptive, and treatment of: uterine fibroids, endometriosis, major depression with psychotic features, glaucoma, meningiomas, breast cancer, ovarian cancer, prostate cancer, and some types of Cushing's syndrome.

Hazard Codes: T
Risk Statements: 60-61 
S60:This material and its container must be disposed of as hazardous waste. 
S61:Avoid release to the environment. Refer to special instructions / safety data sheets.
Safety Statements: 53-22-36/37/39-45 
S53:Avoid exposure - obtain special instructions before use. 
S22:Do not breathe dust. 
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection. 
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
WGK Germany: 3
RTECS: KG2955000

  Mifepristone , its cas register number is 84371-65-3. It also can be called (11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one ; 11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on ; 17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one ; Corlux ; Mifegyne ; Mifeprex ; Mifepristona ; Mifepristonum .